Biotech Firm Latigo IPOs Planned Overhaul in Biotechnology
Latigo Biotherapeutics’ plans for an IPO reflect a biotechnology IPOs overhaul as firms consider public markets this quarter to raise capital for non-opioid —
IBI Inflammatory Bowel Disease Drug Trial Takeover Potential
The focus is on ibi inflammatory bowel disease drug trial takeover potential. Updates as details emerge.
Odyssey Therapeutics Files for U.S. IPO as Drug Developer
Odyssey Therapeutics’ drug developer IPO plans reflect a renewed push into public markets amid biotech investor demand, with focus on autoimmune and
AstraZeneca CSPC drug deal: $1.2B for eight drug candidates
The AstraZeneca CSPC drug deal signifies a strategic move by AstraZeneca to expand its portfolio through acquisition of eight drug candidates from CSPC for
TheraVectys Hong Kong IPO Still Under Consideration Amid
TheraVectys Hong Kong IPO is reportedly being considered by the biotech firm, highlighting Hong Kong's growing appeal as a financial hub for international
Sanofi Dren Bio deal: $1.8B collaboration in immune medicine
The Sanofi Dren Bio deal involves Sanofi's acquisition of Dren Bio in a potential $1.8 billion investment to expand its immunology portfolio and develop
Biotech Natural Metal Extraction: Genomines Uses Plants to
Biotech natural metal extraction, as developed by Genomines, represents a promising sustainable approach to mineral sourcing that aims to reduce environmental